Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: physical function

Health Canada Approves CT-P13 SC for RA; Plus Tofacitinib May Increase Cardiac & Cancer Risks

Michele B. Kaufman, PharmD, BCGP  |  March 5, 2021

In Canada, a subcutaneous formulation of CT-P13, which is biosimilar to infliximab, was approved to treat rheumatoid arthritis.

Filed under:Biologics/DMARDsConditions Tagged with:CanadaCT-P13Drug SafetyFDAinfliximabRheumatoid Arthritis (RA)Tofacitinib

European Commission Approves Upadacitinib for Psoriatic Arthritis & Ankylosing Spondylitis

Michele B. Kaufman, PharmD, BCGP  |  February 4, 2021

In January, upadacitinib was approved for use in Europe as a 15 mg, once-daily dose to treat patients with psoriatic arthritis and ankylosing spondylitis.

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:Ankylosing SpondylitisEuropean UnionPsoriatic Arthritisupadacitinib

A High HAQ at Baseline in Early RA Is a Bad Sign

Arthritis & Rheumatology  |  January 26, 2021

In this study, Fatima et al. analyzed how well the Health Assessment Questionnaire (HAQ) disability index predicts future all-cause mortality in patients with early RA (i.e., with a symptom duration of less than one year). A total of 1,724 patients with early RA were included. The researchers found that a higher HAQ score and Disease Activity Score at one year were significantly associated with all-cause mortality.

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Arthritis & RheumatologyHAQHealth Assessment Questionnaire (HAQ)mortalityResearchRheumatoid Arthritis (RA)

Risankizumab May Improve Symptoms of PsA

Michele B. Kaufman, PharmD, BCGP  |  January 21, 2021

Results from two recent phase 3 clinical trials show risankizumab significantly improved the skin and joint symptoms of patients with psoriatic arthritis compared with placebo.

Filed under:Drug Updates Tagged with:PsAPsoriatic Arthritisrisankizumab

A Pandemic of Psychological Distress Is Upon Us

Tamar Rubinstein, MD, Natoshia Cunningham, PhD, & Andrea Knight, MD, MSCE  |  January 20, 2021

It is nine months into the COVID-19 pandemic in the U.S. and the third wave is upon us, overwhelming hospital systems in many states across the country. But the alarms are being sounded for another looming pandemic as well. As early as spring 2020, significant increases were documented in the prevalence of depression and anxiety,…

Filed under:ConditionsPatient Perspective Tagged with:COVID-19Mental Health

Tofacitinib Promising for Adults with AS

Michele B. Kaufman, PharmD, BCGP  |  November 24, 2020

According to a recent phase 3 study, tofacitinib may be a safe and effective treatment for adult patients with ankylosing spondylitis (AS).

Filed under:Drug Updates

Studies Examine Peripheral Nervous System Disease in Lupus Patients

Linda Childers  |  November 12, 2020

Although systemic lupus erythematosus (SLE) affects both the central nervous system (CNS) and peripheral nervous system (PNS), past research has primarily focused on how lupus affects the CNS. Now, an international, inception cohort study, “Peripheral Nervous System Disease in Systemic Lupus Erythematosus,” published in Arthritis & Rheumatology, has examined different types of PNS disease to…

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:central nervous systemperipheral nervous systemquality of life

Rheumatology Health Educators Educate & Empower Patients

Linda Childers  |  October 19, 2020

As a health educator at Integrative Rheumatology, a private practice in Charlotte, N.C., Latisha Williams, MPH, CHES, CHC, works with patients to teach them how to better manage their disease. In the two-and-a-half years that Ms. Williams has worked at Integrative Rheumatology, she’s answered countless questions about exercise, nutrition and complementary therapies, among other topics. “Patients…

Filed under:Patient PerspectivePractice Support Tagged with:Association of Rheumatology Professionals (ARP)health educationpatient education

Nerve Growth Factor Inhibitor Study Highlights Promise as an OA Pain Treatment

Ruth Jessen Hickman, MD  |  October 1, 2020

A study highlights the potential of fasinumab, an anti-nerve growth factor monoclonal antibody, as a pain treatment for osteoarthritis (OA) patients. Research into the risks and benefits of this therapeutic class for OA are ongoing…

Filed under:Drug UpdatesOsteoarthritis and Bone DisordersResearch Rheum Tagged with:Arthritis & RheumatologyfasinumabKnee Osteoarthritis (OA)Nerve growth factor (NGF)osteoarthritis (OA)tanezumab

FDA Receives Upadacitinib Application for Ankylosing Spondylitis & Approves Tramadol Hydrochloride Oral Solution

Michele B. Kaufman, PharmD, BCGP  |  September 30, 2020

In August, Abbvie submitted a new drug application for upadacitinib to treat ankylosing spondylitis. And in September, the FDA approved an oral solution of tramadol hydrochloride for pain.

Filed under:Axial SpondyloarthritisDrug Updates Tagged with:Ankylosing SpondylitisAS Resource CenterFDAPainPain Managementtramadol hydrochlorideU.S. Food and Drug Administration (FDA)upadacitinib

  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 80
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences